XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease
Dose Finding Pilot Study of Cabozantinib (XL184) Administered Orally as Monotherapy for the Treatment of Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With Bone Disease
Sponsor: Massachusetts General Hospital
Listed as NCT01582295, this PHASE1 trial focuses on Multiple Myeloma and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Mar 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .